Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 21, Issue 4, 2006, Pages 329-350

  D'Cruz, Osmond J ^a   Uckun, Fatih M ^b  

^a PARKER HUGHES INSTITUTE   (United States)

^b Paradigm Pharmaceuticals   (United States)

Author keywords

Combination regimen; Computer aided drug design; HIV AIDS; Inhibition; Non nucleoside inhibitors; Reverse transcriptase; Thiourea compounds

Indexed keywords

1 [(2 HYDROXYETHOXY)METHYL] 6 (PHENYLTHIO)THYMINE; 1 PHENYL 3 (2 THIAZOLYL)THIOUREA; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BETA FLUORO(2 PHENETHYL) N' [2 (5 BROMOPYRIDYL)]THIOUREA; DELAVIRDINE; DNA; LIGAND; N [1 (1 ADAMANTYL)METHYL] N' [2 (THIAZOLYL)]THIOUREA; N [1 (1 ALPHA METHYLBENZYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; N [1 (1 CYCLOHEXYLETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; N [1 (1 CYCLOHEXYLETHYL)] N' [2 (THIAZOLYL)]THIOUREA; N [1 (1 FUROLMETHYL)] N' [2 (THIAZOLYL)]THIOUREA; N [2 (1 CYCLOHEXENYL)ETHYL] N' [2 (5 BROMOPYRIDYL)]THIOUREA; N [2 (2 CHLOROPHENETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; N [2 (2 FLUOROPHENETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; N [2 (2 METHYLPIPERIDINYLETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; N [2 (2 THIOPHENE)ETHYL] N' [2 (5 BROMOPYRIDYL)]THIOUREA; N [2 (2,5 DIMETHOXYPHENYLETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; N [2 (3 FLUOROPHENETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; N [2 (4 METHYLPHENETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; NEVIRAPINE; PHI 236; PHI 240; PHI 241; PHI 244; PHI 253; PHI 346; PHI 443; PHI 509; PHI 511; PHI 513; PHI 516; PHI 535; PHI 536; PHI 565; PROTEINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIOUREA DERIVATIVE; TROVIRDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DERIVATIZATION; DRUG BINDING SITE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR MODEL; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; WILD TYPE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG INDUSTRY; HIV; HIV REVERSE TRANSCRIPTASE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; MUTATION; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; THIAZOLES; THYMINE; TRIAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33748500440     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360600774413     Document Type: Review

References (127)

1. Chaisson RE. HIV becomes world's leading infectious cause of death, The Hopkins HIV report-July 1999. Available from: http://www.aegis.com/pubs/ jhopkins/1999/JH990702.html
2. Worldwide HIV & AIDS epidemic statistics, World estimates of the HIV & AIDS epidemics at the end of 2005. Available from: http://www.avert.org/worldstats.htm
3. Palella, FJ, Jr and Delaney, KM and Moorman, AC and Loveless, MO and Fuhrer, J and Satten, GA and Aschman, DJ and Holmberg, SD. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators N Engl J Med, 338, pp. 853-860.
4. Smit, C and Geskus, R and Uitenbroek, D and Mulder, D and Van Den Hoek, A and Coutinho, RA and Prins, M. (2004) Declining AIDS mortality in Amsterdam: Contributions of declining HIV incidence and effective therapy Epidemiology, 15, pp. 536-542.
5. Yeni, P and Hammer, S and Hirsch, M and Saag, MS and Schechter, M and Carpenter, CC and Fischl, MA and Gatell, JM and Gazzard, BG and Jacobsen, DM and Katzenstein, DA and Montaner, JS and Richman, DD and Schooley, RT and Thompson, MA and Vella, S and Volberding, PA. (2004) Treatment for adult HIV infection: 2004 recommendations of the international AIDS society USA panel JAMA, 292, pp. 251-265.
6. Bogaards, JA and Goudsmit, J. (2003) Meeting the immense need for HAART in resource-poor settings J Antimicrob Chemother, 52, pp. 743-746.
7. Moatti, JP and N'Doye, I and Hammer, SM and Hale, P and Kazatchkine, M. (2003) Antiretroviral treatment for HIV infection in developing countries: An attainable new paradigm Nat Med, 9, pp. 1449-1452.
8. Craigo, JK and Patterson, BK and Paranjpe, S and Kulka, K and Ding, M and Mellors, J and Montelaro, RC and Gupta, P. (2004) Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy AIDS Res Hum Retroviruses, 20, pp. 1196-1209.
9. Hirsch, M and Brun-Vézinet, F and Clotet, B and Conway, B and Kuritzkes, DR and D'Aquila, RT and Demeter, LM and Hammer, SM and Johnson, VA and Loveday, C and Mellors, JW and Jacobsen, DM and Richman, DD. (2003) Antiretroviral drug resistance testing in adults infected with HIV-1: 2003 recommendations of an International AIDS Society USA Panel Clin Infect Dis, 37, pp. 113-128.
10. HIV and AIDS statistics and features, end of 2002 and 2004. North America, Western and Central Europe. Available from: http://www.unaids.org/wad2004/EPIupdate2004_html_en/Epi04_12_en.htm.
11. Wensing, AM and van de Vijver, DA and Angarano, G and Asjo, B and Balotta, C and Boeri, E and Camacho, R and Chaix, ML and Costagliola, D and De Luca, A and Derdelinckx, I and Grossman, Z and Hamouda, O and Hatzakis, A and Hemmer, R and Hoepelman, A and Horban, A and Korn, K and Kucherer, C and Leitner, T and Loveday, C and MacRae, E and Maljkovic, I and de Mendoza, C and Meyer, L and Nielsen, C and Op de Coul, EL and Ormaasen, V and Paraskevis, D and Perrin, L and Puchhammer-Stockl, E and Ruiz, L and Salminen, M and Schmit, JC and Schneider, F and Schuurman, R and Soriano, V and Stanczak, G and Stanojevic, M and Vandamme, AM and Van Laethem, K and Violin, M and Wilbe, K and Yerly, S and Zazzi, M and Boucher, CA. (2005) SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management J Infect Dis, 192, pp. 958-966.
12. Richman, DD and Morton, SC and Wrin, T and Hellmann, N and Berry, S and Shapiro, MF and Bozzette, SA. (2004) The prevalence of antiretroviral drug resistance in the United States AIDS, 18, pp. 1393-1401.
13. De Clercq, E. (2004) Antiviral drugs in current clinical use J Clin Virol, 30, pp. 115-133.
14. Gulick, RM. (2003) New antiretroviral drugs Clin Microbiol Infect, 9, pp. 186-193.
15. Seminari, E and Maggiolo, F and Villani, P and Suter, F and Pan, A and Regazzi, MB and Paolucci, S and Baldanti, F and Tinelli, C and Maserati, R. (1999) Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors J Acquir Immune Defic Syndr, 22, pp. 453-460.
16. Clumeck, n and Goebel, F and Rozenbaum, W and Gerstoft, J and Staszewski, S and Montaner, J and Johnson, M and Gazzard, B and Stone, C and Athisegaran, R and Moore, S. (2001) CNA30017 study team. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA AIDS, 15, pp. 1517-1526.
17. Jordan, WC and Jefferson, R and Yemofio, F and Tolbert, L and Conlon, V and Carroll, H and Green, DC and Green, A and Green, R. (2003) Nevirapine plus efavirenz plus didanosine: A simple, safe, and effective once-daily regimen for patients with HIV infection J Natl Med Assoc, 95, pp. 1152-1157.
18. Chen, D and Misra, A and Garg, A. (2002) Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients J Clin Endocrinol Metab, 87, pp. 4845-4856.
19. Montaner, JS and Reiss, P and Cooper, D and Vella, S and Harris, M and Conway, B and Wainberg, MA and Smith, D and Robinson, P and Hall, D and Myers, M and Lange, JM. (1998) A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial, Italy, The Netherlands, Canada and Australia Study JAMA, 279, pp. 930-937.
20. van Leeuwen, R and Katlama, C and Murphy, RL and Squires, K and Gatell, J and Horban, A and Clotet, B and Staszewski, S and van Eeden, A and Clumeck, N and Moroni, M and Pavia, AT and Schmidt, RE and Gonzalez-Lahoz, J and Montaner, J and Antunes, F and Gulick, R and Banhegyi, D and van der Valk, M and Reiss, P and van Weert, L and van Leth, F and Johnson, VA and Sommadossi, JP and Lange, JM. (2003) A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients AIDS, 17, pp. 987-999.
21. Sulkowski, MS and Mehta, SH and Chaisson, RE and Thomas, DL and Moore, RD. (2004) Hepatoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir AIDS, 18, pp. 2277-2284.
22. Young, J and Weber, R and Rickenbach, M and Furrer, H and Bernasconi, E and Hirschel, B and Tarr, PE and Vernazza, P and Battegay, M and Bucher, HC. (2005) Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study Antivir Ther, 10, pp. 585-591.
23. Tebas, P and Yarasheski, K and Henry, K and Claxton, S and Kane, E and Bordenave, B and Klebert, M and Powderly, WG. (2004) Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection AIDS Res Hum Retroviruses, 20, pp. 589-594.
24. Barreiro, P and García-Benayas, T and Soriano, V and Gallant, J. (2002) Simplification of antiretroviral treatment: How to sustain success, reduce toxicity and ensure adherence avoiding PI use AIDS Rev, 4, pp. 233-241.
25. French, M and Amin, J and Roth, N and Carr, A and Law, M and Emery, S and Drummond, F and Cooper, D. (2002) OzCombo 2 investigators. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study HIV Clin Trials, 3, pp. 177-185.
26. Lange, JM. (2003) Efficacy and durability of nevirapine in antiretroviral drug naive patients Suppl 1, 34, pp. S40-S52. (Suppl 1)
27. van Leth, F and Phanuphak, P and Ruxrungtham, K and Baraldi, E and Miller, S and Gazzard, B and Cahn, P and Lalloo, UG and van der Westhuizen, IP and Malan, DR and Johnson, MA and Santos, BR and Mulcahy, F and Wood, R and Levi, GC and Reboredo, G and Squires, K and Cassetti, I and Petit, D and Raffi, F and Katlama, C and Murphy, RL and Horban, A and Dam, JP and Hassink, E and van Leeuwen, R and Robinson, P and Wit, FW and Lange, JM. (2004) 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study Lancet, 363, pp. 1253-1263.
28. Luzuriaga, K and McManus, M and Mofenson, L and Britto, P and Graham, B and Sullivan, JL. (2004) PACTG 356 Investigators. A trial of three antiretroviral regimens in HIV-1-infected children N Engl J Med, 350, pp. 2471-2480.
29. Pedersen, OS and Pedersen, EB. (1999) Non-nucleoside reverse transcriptase inhibitors: The NNRTI boom Antivir Chem Chemother, 10, pp. 285-314.
30. Campiani, G and Ramunno, A and Maga, G and Nacci, V and Fattorusso, C and Catalanotti, B and Morelli, E and Novellino, E. (2002) Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives Curr Pharm Des, 8, pp. 615-657.
31. Smerdon, SJ and Jager, J and Wang, J and Kohlstaedt, LA and Chirino, AJ and Friedman, JM and Rice, PA and Steitz, TA. (1994) Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1 Proc Natl Acad Sci USA, 91, pp. 3911-3915.
32. Tantillo, C and Ding, J and Jacobo-Molina, A and Nanni, RG and Boyer, PL and Hughes, SH and Pauwels, R and Andries, K and Janssen, PA and Arnold, E. (1994) Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance J Mol Biol, 243, pp. 369-387.
33. Ding, J and Das, K and Hsiou, Y and Sarafianos, SG and Clark, AD, Jr and Jacobo-Molina, A and Tantillo, C and Hughes, SH and Arnold, E. (1995) Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution Structure, 3, pp. 365-379.
34. Esnouf, R and Ren, J and Ross, C and Jones, Y and Stammers, D and Stuart, D. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors Nat Struct Biol, 2, pp. 303-308.
35. Merluzzi, VJ and Hargrave, KD and Labadia, M and Grozinger, K and Skoog, M and Wu, JC and Shih, CK and Eckner, K and Hattox, S and Adams, J and Rosenthal, AS and Faanes, R and Eckner, RJ and Koup, RA and Sullivan, JL. (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor Science, 250, pp. 1411-1413.
36. Romero, DL and Busso, M and Tan, CK and Reusser, F and Palmer, JR and Poppe, SM and Aristoff, PA and Downey, KM and So, AG and Resnick, L and Tarpley, WG. (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication Proc Natl Acad Sci USA, 88, pp. 8806-8810.
37. Young, SD and Britcher, SF and Tran, LO and Payne, LS and Lumma, WC and Lyle, TA and Huff, JR and Anderson, PS and Olsen, DB and Carroll, SS and Pettibone, DJ and O'Brien, JA and Ball, RG and Balani, SK and Linn, JH and Chen, I-W and Schleif, WA and Sardana, VV and Long, WJ and Byrnes, VW. (1995) Emini EA, L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase Antimicrob Agents Chemother, 39, pp. 2602-2605.
38. Staszewski, S and Morales-Ramirez, J and Tashima, KT and Rachlis, A and Skiest, D and Stanford, J and Stryker, R and Johnson, P and Labriola, DF and Farina, D and Manion, DJ and Ruiz, NM. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team N Engl J Med, 341, pp. 1865-1873.
39. van Leeuwen, R and Katlama, C and Murphy, RL and Squires, K and Gatell, J and Horban, A and Clotet, B and Staszewski, S and van Eeden, A and Clumeck, N and Moroni, M and Pavia, AT and Schmidt, RE and Gonzalez-Lahoz, J and Montaner, J and Antunes, F and Gulick, R and Banhegyi, D and van der Valk, M and Reiss, P and van Weert, L and van Leth, F and Johnson, VA and Sommadossi, JP and Lange, JM. (2003) A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients AIDS, 17, pp. 987-999.
40. Robbins, GK and De Gruttola, V and Shafer, RW and Smeaton, LM and Snyder, SW and Pettinelli, C and Dube, MP and Fischl, MA and Pollard, RB and Delapenha, R and Gedeon, L and van der Horst, C and Murphy, RL and Becker, MI and D'Aquila, RT and Vella, S and Merigan, TC and Hirsch, MS. (2003) AIDS clinical trials group 384 team. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection N Engl J Med, 349, pp. 2293-2303.
41. US Department of Health and Human Services Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. October 6, 2005. Available from: http://www.aidsinfo.nih.gov/guidelines/ GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off& GuidelineID=7&ClassID=1
42. Palella, FJ, Jr. and Deloria-Knoll, M and Chmiel, JS and Moorman, AC and Wood, KC and Greenberg, AE and Holmberg, SD. (2003) HIV outpatient study investigators. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata Ann Intern Med, 138, pp. 620-626.
43. Wilkin, TJ and Gulick, RM. (2003) Antiretroviral therapy: When and what to start- an american perspective Curr Infect Dis Rep, 5, pp. 339-348.
44. Richman, D and Shih, CK and Lowy, I and Rose, J and Prodanovich, P and Goff, S and Griffin, J. (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture Proc Natl Acad Sci USA, 88, pp. 11241-11245.
45. Richman, DD and Havlir, D and Corbeil, J and Looney, D and Ignacio, C and Spector, SA and Sullivan, J and Cheeseman, S and Barringer, K and Pauletti, D and Shih, C-K and Myers, M and Griffin, J. (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy J Virol, 68, pp. 1660-1666.
46. Deeks, SG. (2001) Non nucleoside reverse transcriptase inhibitor resistance J Acquir Immune Defic Syndr, 26(Suppl 1), pp. S25-S33.
47. Bacheler, L and Jeffrey, S and Hanna, G and D'Aquila, R and Wallace, L and Logue, K and Cordova, B and Hertogs, K and Larder, B and Buckery, R and Baker, D and Gallagher, K and Scarnati, H and Tritch, R and Rizzo, C. (2001) Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy J Virol, 75, pp. 4999-5008.
48. Artico, M. (1996) Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): A chemical survey from lead compounds to selected drugs for clinical trials Farmaco, 51, pp. 305-331.
49. Casado, JL and Hertogs, K and Ruiz, L and Dronda, F and Van Cauwenberge, A and Arno, A and Garcia-Arata, I and Bloor, S and Bonjoch, A and Blazquez, J and Clotet, B and Larder, B. (2000) Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen AIDS, 14, pp. F1-F7.
50. Albrecht, MA and Bosch, RJ and Hammer, SM and Liou, SH and Kessler, H and Para, MF and Eron, J and Valdez, H and Dehlinger, M and Katzenstein, DA. (2001) AIDS clinical trials group 364 study team. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection N Engl J Med, 345, pp. 398-407.
51. Delaugerre, C and Rohban, R and Simon, A and Mouroux, M and Tricot, C and Agher, R and Huraux, JM and Katlama, C and Calvez, V. (2001) Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen J Med Virol, 65, pp. 445-448.
52. Clevenbergh, P and Cua, E and Dam, E and Durant, J and Schmit, JC and Boulme, R and Cottalorda, J and Beyou, A and Schapiro, JM and Clavel, F and Dellamonica, P. (2002) Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naive HIV-infected patients HIV Clin Trials, 3, pp. 36-44.
53. Joly, V and Descamps, D and Peytavin, G and Touati, F and Mentre, F and Duval, X and Delarue, S and Yeni, P and Brun-Vezinet, F. (2004) Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs Antimicrob Agents Chemother, 48, pp. 172-175.
54. Hachiya, A and Gatanaga, H and Kodama, E and Ikeuchi, M and Matsuoka, M and Harada, S and Mitsuya, H and Kimura, S and Oka, S. (2004) Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naive patients Virology, 327, pp. 215-224.
55. Delaguerre, C and Rohban, R and Simon, A and Mouroux, M and Tricot, C and Agher, R and Huraux, JM and Katlama, C and Calvez, V. (2001) Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen J Med Virol, 65, pp. 445-448.
56. Hanna, GJ and Johnson, VA and Kuritzkes, DR and Richman, DD and Brown, AJ and Savara, AV and Hazelwood, JD and D'Aquila, RT. (2000) Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine J Infect Dis, 181, pp. 904-911.
57. Eshleman, SH and Krogstad, P and Jackson, JB and Wang, YG and Lee, S and Wei, LG and Cunningham, S and Wantman, M and Wiznia, A and Johnson, G and Nachman, S and Palumbo, P. (2001) Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir J Infect Dis, 183, pp. 1732-1738.
58. Bacheler, LT and Anton, ED and Kudish, P and Baker, D and Bunville, J and Krakowski, K and Bolling, L and Aujay, M and Wang, XV and Ellis, D and Becker, MF and Lasut, AL and George, HJ and Spalding, DR and Hollis, G and Abremski, K. (2000) Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy Antimicrob Agents Chemother, 44, pp. 2475-2484.
59. Demeter, LM and Shafer, RW and Meehan, PM and Holden-Wiltse, J and Fischl, MA and Freimuth, WW and Para, MF and Reichman, RC. (2000) Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260) Antimicrob Agents Chemother, 44, pp. 794-797.
60. Joly, V and Moroni, M and Concia, E and Lazzarin, A and Hirschel, B and Jost, J and Chiodo, F and Bentwich, Z and Love, WC and Hawkins, DA and Wilkins, EGL and Gatell, AJ and Vetter, N and Greenwald, C and Freimuth, WW and de Cian, W and and M/3331/0013B Study Group. (2000) Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial Antimicrob Agents Chemother, 44, pp. 3155-3157.
61. Shulman, N and Zolopa, AR and Passaro, D and Shafer, RW and Huang, W and Katzenstein, D and Israelski, DM and Hellmann, N and Petropoulos, C and Whitcomb, J. (2001) Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: Impact on virological response to efavirenz-based therapy AIDS, 15, pp. 1125-1132.
62. Whitcomb, JM and Huang, W and Limoli, K and Paxinos, E and Wrin, T and Skowron, G and Deeks, SG and Bates, M and Hellmann, NS and Petropoulos, CJ. (2002) Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: Clinical, phenotypic and genotypic correlates AIDS, 16, pp. F41-F47.
63. Antinori, A and Zaccarelli, M and Cingolani, A and Forbici, F and Rizzo, MG and Trotta, MP and Di Giambenedetto, S and Narciso, P and Ammassari, A and Girardi, E and De Luca, A and Perno, CF. (2002) Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure AIDS Res Hum Retrovir, 18, pp. 835-838.
64. Bacheler, LT. (1999) Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase Drug Resist Updates, 2, pp. 56-67.
65. Hsiou, Y and Das, K and Ding, J and Clark, AD, Jr and Kleim, JP and Rosner, M and Winkler, I and Riess, G and Hughes, SH and Arnold, E. (1998) Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: Inhibitor flexibility is a useful design feature for reducing drug resistance J Mol Biol, 284, pp. 313-323.
66. Pelemans, H and Esnouf, R and De Clercq, E and Balzarini, J. (2000) Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors Mol Pharmacol, 57, pp. 954-960.
67. Bell, FW and Cantrell, AS and Hogberg, M and Jaskunas, SR and Johansson, NG and Jordan, CL and Kinnick, MD and Lind, P and Morin, JM, Jr and Noreen, R and Oberg, B and Palkowitz, JA and Parrish, CA and Pramo, P and Sahlberg, C and Ternansky, RT and Vasileff, RT and Vrang, L and West, SJ and Zhang, H and Zhou, XX. (1995) Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors 1. Synthesis and basic structure-activity relationship studies of PETT analogs J Med Chem, 38, pp. 4929-4936.
68. Cantrell, AS and Engelhardt, P and Hogberg, M and Jaskunas, SR and Johansson, NG and Jordan, CL and Kangasmetsa, J and Kinnick, MD and Lind, P and Morin, JM, Jr and Muesing, MA and Noreen, R and Oberg, B and Pranc, P and Sahlberg, C and Ternansky, RJ and Vasileff, RT and Vrang, L and West, SJ and Zhang, H. (1996) Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors 2. Synthesis and further structure-activity relationship studies of PETT analogs J Med Chem, 39, pp. 4261-4274.
69. Vig, R and Mao, C and Venkatachalam, TK and Tuel-Ahlgren, L and Sudbeck, EA and Uckun, FM. (1998) Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase Bioorg Med Chem, 6, pp. 1789-1797.
70. Vig, R and Mao, C and Venkatachalam, TK and Tuel-Ahlgren, L and Sudbeck, EA and Uckun, FM. (1998) 5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series Bioorg Med Chem Lett, 8, pp. 1461-1466.
71. Sudbeck, EA and Mao, C and Vig, R and Venkatachalam, TK and Tuel-Ahlgren, L and Uckun, FM. (1998) Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase Antimicrob Agents Chemother, 42, pp. 3225-3233.
72. Mao, C and Vig, R and venkatachalam, TK and Sudbeck, EA and Uckun, FM. (1998) Structure-based design of N-[2-(1-piperidinylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase Bioorg Med Chem Lett;, 8, pp. 2213-2218.
73. D'Cruz, OJ and Uckun, FM. (1999) Novel derivatives of phenethyl-5-bromopyridylthiourea and dihydroalkoxybenzyloxopyrimidine are dual-function spermicides with potent anti-human immunodeficiency virus activity Biol Reprod, 60, pp. 1419-1428.
74. Sudbeck, EA and Jennissen, JD and Venkatachalam, TK and Uckun, FM. (1999) Inhibitor of HIV-1 reverse transcriptase: N′-(5-bromo-2-pyridyl)-N-[2-(2,5-dimethoxyphenyl)ethyl] thiourea Acta Crystallogr C, 55, pp. 2122-2124.
75. Uckun, FM and Pendergrass, S and Maher, D and Zhu, D and Tuel-Ahlgren, L and Mao, C and Venkatachalam, TK. (1999) N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1 Bioorg Med Chem Lett, 9, pp. 3411-3416.
76. Mao, C and Sudbeck, EA and Venkatachalam, TK and Uckun, FM. (1999) Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus Antivir Chem Chemother, 10, pp. 233-240.
77. Uckun, FM and Mao, C and Pendergrass, S and Maher, D and Zhu, D and Tuel-Ahlgren, L and Venkatachalam, TK. (1999) N-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea and
78. D'Cruz, OJ and Venkatachalam, TK and Uckun, FM. (2000) Novel thiourea compounds as dual-function microbicides Biol Reprod, 63, pp. 196-205.
79. Mao, C and Sudbeck, EA and Venkatachalam, TK and Uckun, FM. (1999) Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus Bioorg Med Chem Lett, 9, pp. 1593-1598.
80. Mao, C and Sudbeck, EA and Venkatachalam, TK and Uckun, FM. (2000) Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase Biochem Pharmacol, 60, pp. 1251-1265.
81. Venkatachalam, TK and Sudbeck, EA and Mao, C and Uckun, FM. (2000) Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase Bioorg Med Chem Lett, 10, pp. 2071-2074.
82. D'Cruz, OJ and Samuel, P and Uckun, FM. (2005) Conceival: A novel noncontraceptive vaginal vehicle for lipophilic microbicides AAPS Pharm Sci Tech, 6, pp. E56-E64. Available from: http://www.aapspharmscitech.org/view.asp?art=pt060111
83. Uckun, FM and Mao, C and Pendergrass, S and Maher, D and Zhu, D and Tuel-Ahlgren, L and Venkatachalam, TK. (2000) N-[2-(4-methylphenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea as a potent inhibitor of NNRTI-resistant and multidrug-resistant human immunodeficiency virus type 1 Antivir Chem Chemother, 11, pp. 135-140.
84. Venkatachalam, TK and Sudbeck, EA and Mao, C and Uckun, FM. (2000) Piperidinylethyl, phenoxyethyl and fluoroethyl bromopyridyl thiourea compounds with potent anti-HIV activity Antivir Chem Chemother, 11, pp. 329-336.
85. Venkatachalam, TK and Sudbeck, EA and Mao, C and Uckun, FM. (2001) Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds Bioorg Med Chem Lett, 11, pp. 523-528.
86. D'Cruz, OJ and Samuel, P and Uckun, FM. (2004) PHI-443: A novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide Biol Reprod, 71, pp. 2037-2047.
87. D'Cruz, OJ and Uckun, FM. (2005) Discovery of 2-5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human immunodeficiency virus microbicide Mol Hum Reprod, 11, pp. 767-777.
88. Mulky, A and Kappes, JC. (2005) Analysis of human immunodeficiency virus type 1 reverse transcriptase subunit structure/function in the context of infectious virions and human target cells Antimicrob Agents Chemother, 49, pp. 3762-3769.
89. Shen, L and Shen, J and Luo, X and Cheng, F and Xu, Y and Chen, K and Arnold, E and Ding, J and Jiang, H. (2003) Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT Biophys J, 84, pp. 3547-3563.
90. Kohlstaedt, LA and Wang, J and Friedman, JM and Rice, PA and Steitz, TA. (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor Science, 256, pp. 1783-1790.
91. Ren, J and Esnouf, R and Garman, E and Somers, D and Ross, C and Kirby, I and Keeling, J and Darby, G and Jones, Y and Stuart, D and Stammers, D. (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes Nat Struct Biol, 2, pp. 293-302.
92. Hopkins, AL and Ren, J and Esnouf, RM and Willcox, BE and Jones, EY and Ross, C and Miyasaka, T and Walker, RT and Tanaka, H and Stammers, DK and Stuart, DI. (1996) Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors J Med Chem, 39, pp. 1589-1600.
93. Schafer, W and Friebe, WG and Leinert, H and Mertens, A and Poll, T and von der Saal, W and Zilch, H and Nuber, B and Ziegler, ML. (1993) Non-nucleoside inhibitors of HIV-1 reverse transcriptase: Molecular modeling and X-ray structure investigations J Med Chem, 36, pp. 726-732.
94. Ren, J and Esnouf, RM and Hopkins, AL and Warren, J and Balzarini, J and Stuart, DI and Stammers, DK. (1998) Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives Biochemistry, 37, pp. 14394-14403.
95. Larder, BA. (1994) Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase J Gen Virol, 75, pp. 951-957.
96. Huang, H and Chopra, R and Verdine, GL and Harrison, SC. (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance Science, 282, pp. 1669-1675.
97. Hsiou, Y and Das, K and Ding, J and Clark, AD, Jr and Kleim, JP and Rosner, M and Winkler, I and Riess, G and Hughes, SH and Arnold, E. (1998) Structure of tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: Inhibitor flexibility is a useful design feature for reducing drug resistance J Mol Biol, 284, pp. 313-323.
98. Abrahao-Junior, O and Nascimento, PG and Galembeck, SE. (2001) Conformational analysis of the HIV-1 virus reverse transcriptase nonnucleoside inhibitors: TIBO and nevirapine J Comput Chem, 22, pp. 1817-1829.
99. Molecular Simulations Inc. (1996) InsightII. San Diego, CA: Molecular Simulations Inc.
100. Bohm, HJ. (1994) The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure J Comput Aided Mol Des, 8, pp. 243-256.
101. Bohm, HJ. (1992) LUDI: Rule-based automatic design of new substituents for enzyme inhibitor leads J Comput-Aided Mol Des, 6, pp. 593-606.
102. Luty, BA and Wasserman, ZR and Stouten, PFW and Hodge, CN and Zacharias, M and McCammon, JA. (1995) A molecular mechanics/grid method for evaluation of ligand-receptor interactions J Comp Chem, 16, pp. 454-464.
103. Brodine, SK and Mascola, JR and Weiss, PJ and Ito, SI and Porter, KR and Artenstein, AW and Garland, FC and McCutchan, FE and Burke, DS. (1995) Detection of diverse HIV-1 genetic subtypes in the USA Lancet, 346, pp. 1198-1199.
104. Schinazi, RF and Larder, BA and Mellors, JW. (1997) Mutations in retroviral genes associated with drug resistance Int Antiviral News, 5, pp. 129-135.
105. Marcelin, AG and Delaugerre, C and Wirden, M and Viegas, P and Simon, A and Katlama, C and Calvez, V. (2004) Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure J Med Virol, 72, pp. 162-165.
106. Rapatski, BL and Suppe, F and Yorke, JA. (2005) HIV epidemics driven by late disease stage transmission J Acquir Immune Defic Syndr, 38, pp. 241-253.
107. D'Cruz, OJ and Venkatachalam, TK and Mao, C and Qazi, S and Uckun, FM. (2002) Structural requirements for potent anti-human immunodeficiency virus (HIV) and sperm-immobilizing activities of cyclohexenyl thiourea and urea non-nucleoside inhibitors of HIV-1 reverse transcriptase Biol Reprod, 67, pp. 1959-1974.
108. Venkatachalam, TK and Mao, C and Uckun, FM. (2001) Stereochemistry as a major determinant of the anti-HIV activity of chiral naphthyl thiourea compounds Antivir Chem Chemother, 12, pp. 213-221.
109. Venkatachalam, TK and Mao, C and Uckun, FM. (2004) Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds Bioorg Med Chem, 12, pp. 4275-4284.
110. Venkatachalam, TK and Mao, C and Uckun, FM. (2004) Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: Viral potency of chiral PETT derivatives Biochem Pharmacol, 67, pp. 1933-1946.
111. Venkatachalam, TK and Sudbeck, E and Uckun, FM. (2004) Structural influence on the anisotropic intermolecular hydrogen bonding in solid state of substituted thioureas: Evidence by X-ray crystal structure J Mol Struct, 687, pp. 45-56.
112. Venkatachalam, TK and Sudbeck, E and Uckun, FM. (2004) Structural influence on the solid state intermolecular hydrogen bonding of substituted thioureas J Mol Struct, 751, pp. 45-58.
113. Venkatachalam, TK and Uckun, FM. (2004) Synthesis of β-fluorophenethyl halopyridyl thiourea compounds as non-nucleoside inhibitors of HIV-1 reverse transcriptase Synth Commun, 34, pp. 2462-2472.
114. Venkatachalam, TK and Sudbeck, EA and Mao, C and Uckun, FM. (2000) Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as non-nucleoside inhibitors of HIV-1 reverse transcriptase Bioorg Med Chem Lett, 10, pp. 2071-2074.
115. Venkatachalam, TK and Uckun, FM. (2004) Regiospecific synthesis of 5-halo-substituted thiophene pyridyl thiourea compounds as non-nucleoside inhibitors of HIV-1 reverse transcriptase Synth Commun, 34, pp. 1-11.
116. Chen, CL and Uckun, FM. (1999) Evaluation of the pharmacokinetic features and tissue distribution of the potent nonnucleoside inhibitor of HIV-1 reverse transcriptase, N-[2-(2-fluorophenethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-240) with an analytical HPLC method Pharm Res, 16, pp. 1226-1232.
117. Chen, CL and Venkatachalam, TK and Waurzyniak, B and Chelstrom, L and Uckun, FM. (2001) In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase Arzneimittelforschung, 51, pp. 574-581.
118. D'Cruz, OJ and Waurzyniak, B and Uckun, FM. (2002) A 13-week subchronic intravaginal toxicity study of the novel broad-spectrum anti-HIV and spermicidal agent, N-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea (PHI-346) in mice Toxicol Pathol, 30, pp. 687-695.
119. Zussman, A and Lara, L and Lara, HH and Bentwich, Z and Borkow, G. (2003) Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781 AIDS, 17, pp. 653-661.
120. Van Herrewege, Y and Penne, L and Vereecken, C and Fransen, K and van der Groen, G and Kestens, L and Balzarini, J and Vanham, G. (2002) Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: A possible in vitro model for postexposure prophylaxis of sexual HIV transmission AIDS Res Hum Retrovirlt, 18, pp. 1091-1102.
121. Di Fabio, S and Van Roey, J and Giannini, G and van den Mooter, G and Spada, M and Binelli, A and Pirillo, MF and Germinario, E and Belardelli, F and de Bethune, MP and Vella, S. (2003) Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation AIDS, 17, pp. 1597-1604.
122. Van Herrewege, Y and Michiels, J and Van Roey, J and Fransen, K and Kestens, L and Balzarini, J and Lewi, P and Vanham, G and Janssen, P. (2004) In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides Antimicrob Agents Chemother, 48, pp. 337-339.
123. Njai, HF and Lewi, PJ and Janssen, CG and Garcia, S and Fransen, K and Kestens, L and Vanham, G and Janssen, PA. (2005) Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells Antivir Ther, 10, pp. 255-262.
124. Fletcher, P and Kiselyeva, Y and Wallace, G and Romano, J and Griffin, G and Margolis, L and Shattock, R. (2005) The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells J Virol, 79, pp. 11179-11186.
125. D'Cruz, OJ and Uckun, FM. (2006) Dawn of non-nucleoside inhibitor-based anti-HIV microbicides J Antimicrob Chemother, 57, pp. 411-423.
126. Biosyn, Inc. 2003., Initiates Phase I Clinical Testing of UC-781, a Novel HIV Microbicide. September 4, 2003. http://www.aegis.org/news/pr/2003/PR030908.html.
127. Alliance for Microbicide Development., http://www.microbicide.org.